<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168906</url>
  </required_header>
  <id_info>
    <org_study_id>NEOD001-RAIN</org_study_id>
    <nct_id>NCT03168906</nct_id>
  </id_info>
  <brief_title>Renal AL Amyloid Involvement and NEOD001</brief_title>
  <acronym>RAIN</acronym>
  <official_title>The RAIN Study, a Multicenter Randomized Double-blind Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic Light-chain (AL) Amyloidosis and Persistent Renal Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm,
      parallel-group efficacy and safety study of NEOD001 as a single agent administered
      intravenously in adults with AL amyloidosis who have a maintained hematologic response to
      their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell
      transplant [ASCT]) and have persistent renal dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm,
      parallel-group efficacy and safety study of NEOD001 as a single agent administered
      intravenously in adults with AL amyloidosis who have a maintained hematologic response to
      their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell
      transplant [SCT]) and have persistent renal dysfunction. Subject screening will occur during
      the 28 days prior to the first administration of study drug (i.e. month 1 day 1). If
      screening assessments are completed and all eligibility requirements are met, the subject
      will be enrolled. Study visits will occur every 28 days based on scheduling from month 1 day
      1. A ±5-day window is allowed for visits starting after month 1. Subjects may receive up to
      12 infusions of study drug. Subjects who discontinue study drug before the initial End of
      Study (EOS) visit should have an Early Treatment Discontinuation (ETD) Visit 30 (±5) days
      after their final administration of study drug. After completing 12 months of treatment and
      the confirmatory EOS visit, a subject may enter an open-label extension (OLE) study, during
      which subjects will receive active treatment with NEOD001 for 12 months and may receive
      concurrent chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility
  </why_stopped>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Actual">February 6, 2019</completion_date>
  <primary_completion_date type="Actual">April 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Renal Response After Treatment With NEOD001</measure>
    <time_frame>Baseline to 13 Months</time_frame>
    <description>A renal response is a ≥ 30% reduction in proteinuria in the absence of a ≥ 25% decrease in eGFR. A confirmed renal response is one that has been documented as present one month after 12 monthly treatments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured GFR at Study Entry</measure>
    <time_frame>Baseline</time_frame>
    <description>The aim of this study is to assess the performance of CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine in comparison to iothalamate clearance measured in AL amyloidosis patients. Iothalamate will be given subcutaneously. Urine and plasma samples will then be obtained. All laboratory tests for samples obtained for GFR measurement will be performed at Mayo Clinic Rochester. Quantification of iothalamate in urine and plasma will be performed using a tandem mass spectrometric method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CKD 4 or 5</measure>
    <time_frame>Baseline to 13 Months</time_frame>
    <description>Months to Chronic Kidney Disease level 4 or 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to eGFR ≤ 15 or Dialysis</measure>
    <time_frame>Baseline to 13 Months</time_frame>
    <description>Months to estimated Glomerular Filtration Rate ≤ 15 or dialysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Doubling of Creatinine</measure>
    <time_frame>Baseline to 13 Months</time_frame>
    <description>Months to doubling of serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ≥ 40% Reduction in eGFR</measure>
    <time_frame>Baseline to 13 Months</time_frame>
    <description>Months to ≥ 40% reduction in estimated glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Response in Patients With Maintained Hematologic Responses After 24 Monthly Treatments.</measure>
    <time_frame>Baseline to 26 months</time_frame>
    <description>A renal response is a ≥ 30% decrease in proteinuria or drop of proteinuria below 0.5 g/24h in the absence of renal progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause of Mortality at 26 Months</measure>
    <time_frame>Baseline to 26 months</time_frame>
    <description>Death at 26 months from Baseline due to any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>NEOD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Drug given IV every 28 days at 24mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NEOD001</intervention_name>
    <description>NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates</description>
    <arm_group_label>NEOD001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline bag</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older

          2. Biopsy-proven diagnosis of AL amyloidosis by immunohistochemistry or mass spectroscopy
             of a tissue biopsy excluding bone marrow

          3. Screening renal biopsy for RAIN confirming AL amyloidosis as exclusive or dominant
             cause of renal damage

          4. Persistent renal involvement from diagnosis with proteinuria (predominantly albumin) &gt;
             500mg/day in a 24-hour urine collection

          5. CKD 1 to 3 (eGFR &gt; 30)

          6. ≥1 prior systemic hematologic therapy for a free light chain (FLC) producing
             hematologic malignancy underlying the initial diagnosis of AL amyloidosis with at
             least a partial FLC response (PR, VGPR, CR) to treatment deemed stable and not
             requiring further treatment

          7. ECOG Performance Status ≤ 2

          8. Clinical laboratory values:

               1. Absolute neutrophil count &gt; 1000/μL

               2. Platelet count &gt; 75,000/μL

               3. Total bilirubin ≤ 1.5X ULN

               4. Alkaline phosphatase ≤ 5X ULN

               5. NT-proBNP &lt; 1800 pg/mL

          9. Voluntary written consent must be given before performance of any study-related
             procedure not part of standard medical care with the understanding that consent may be
             withdrawn by the patient at any time without prejudice to future medical care

        Exclusion Criteria:

          1. Amyloidosis due to mutations of the transthyretin gene or presence of other non-AL
             amyloidosis

          2. Female patients who are lactating, breastfeeding, or pregnant

          3. Patients who have not been treated or who have received chemotherapy within 6 months,
             or SCT within 12 months, for the light-chain producing hematologic disease causing AL
             amyloidosis, at the time of the first dose of NEOD001 (month 1 day 1)

          4. Patients who at initial diagnosis or later met the International Myeloma Working Group
             (IMWG) definition of active multiple myeloma requiring therapy (Appendix 3)

          5. Patients whose screening renal biopsies for RAIN show dominant causes of renal damage
             not related to AL amyloidosis

          6. Medically documented cardiac syncope, uncompensated congestive heart failure,
             myocardial infarction within the previous 6 months, unstable angina pectoris,
             clinically significant repetitive atrial or ventricular arrhythmias despite
             antiarrhythmic treatment, or severe orthostatic hypotension or clinically significant
             uncompensated autonomic insufficiency

          7. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          8. Ongoing or active infection, known HIV positive, known to be hepatitis B surface
             antigen-positive or has known or suspected active hepatitis C infection.

          9. Psychiatric illness/social situations that would limit compliance with study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Comenzo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic- Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic- Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic- Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>September 30, 2019</results_first_submitted>
  <results_first_submitted_qc>December 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 24, 2019</results_first_posted>
  <last_update_submitted>December 23, 2019</last_update_submitted>
  <last_update_submitted_qc>December 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloidosis</keyword>
  <keyword>NEOD001</keyword>
  <keyword>RAIN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03168906/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NEOD001</title>
          <description>Study Drug given IV every 28 days at 24mg/kg
NEOD001: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Saline bag</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study discontinued due to futile nature of drug</participants>
                <participants group_id="P2" count="0">Study discontinued due to futile nature of drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NEOD001</title>
          <description>Study Drug given IV every 28 days at 24mg/kg
NEOD001: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Saline bag</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="47" upper_limit="78"/>
                    <measurement group_id="B2" value="54.5" lower_limit="49" upper_limit="68"/>
                    <measurement group_id="B3" value="57.5" lower_limit="47" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Renal Response After Treatment With NEOD001</title>
        <description>A renal response is a ≥ 30% reduction in proteinuria in the absence of a ≥ 25% decrease in eGFR. A confirmed renal response is one that has been documented as present one month after 12 monthly treatments.</description>
        <time_frame>Baseline to 13 Months</time_frame>
        <population>Trial was closed prior to completion, therefore data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>NEOD001</title>
            <description>Study Drug given IV every 28 days at 24mg/kg
NEOD001: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: Saline bag</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Renal Response After Treatment With NEOD001</title>
          <description>A renal response is a ≥ 30% reduction in proteinuria in the absence of a ≥ 25% decrease in eGFR. A confirmed renal response is one that has been documented as present one month after 12 monthly treatments.</description>
          <population>Trial was closed prior to completion, therefore data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measured GFR at Study Entry</title>
        <description>The aim of this study is to assess the performance of CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine in comparison to iothalamate clearance measured in AL amyloidosis patients. Iothalamate will be given subcutaneously. Urine and plasma samples will then be obtained. All laboratory tests for samples obtained for GFR measurement will be performed at Mayo Clinic Rochester. Quantification of iothalamate in urine and plasma will be performed using a tandem mass spectrometric method.</description>
        <time_frame>Baseline</time_frame>
        <population>Trial was closed prior to completion, therefore data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>NEOD001</title>
            <description>Study Drug given IV every 28 days at 24mg/kg
NEOD001: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Measured GFR at Study Entry</title>
          <description>The aim of this study is to assess the performance of CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine in comparison to iothalamate clearance measured in AL amyloidosis patients. Iothalamate will be given subcutaneously. Urine and plasma samples will then be obtained. All laboratory tests for samples obtained for GFR measurement will be performed at Mayo Clinic Rochester. Quantification of iothalamate in urine and plasma will be performed using a tandem mass spectrometric method.</description>
          <population>Trial was closed prior to completion, therefore data were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CKD 4 or 5</title>
        <description>Months to Chronic Kidney Disease level 4 or 5</description>
        <time_frame>Baseline to 13 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to eGFR ≤ 15 or Dialysis</title>
        <description>Months to estimated Glomerular Filtration Rate ≤ 15 or dialysis</description>
        <time_frame>Baseline to 13 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Doubling of Creatinine</title>
        <description>Months to doubling of serum creatinine</description>
        <time_frame>Baseline to 13 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to ≥ 40% Reduction in eGFR</title>
        <description>Months to ≥ 40% reduction in estimated glomerular filtration rate</description>
        <time_frame>Baseline to 13 Months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Response in Patients With Maintained Hematologic Responses After 24 Monthly Treatments.</title>
        <description>A renal response is a ≥ 30% decrease in proteinuria or drop of proteinuria below 0.5 g/24h in the absence of renal progression.</description>
        <time_frame>Baseline to 26 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause of Mortality at 26 Months</title>
        <description>Death at 26 months from Baseline due to any cause</description>
        <time_frame>Baseline to 26 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NEOD001</title>
          <description>Study Drug given IV every 28 days at 24mg/kg
NEOD001: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo
Placebo: Saline bag</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Upper and lower extremity swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right hip pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Left arm pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Coughing spells</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaime Chisholm</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>617-636-5409</phone>
      <email>jchisholm1@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

